← Back to Search

Cancer Vaccine

therapeutic autologous lymphocytes for Brain Cancer (ATTAC Trial)

Phase 1
Waitlist Available
Led By Katherine Peters, MD, PhD
Research Sponsored by Gary Archer Ph.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 months
Awards & highlights

ATTAC Trial Summary

This trial is testing a new cancer vaccine to see if it's effective in treating glioblastoma multiforme, a type of brain cancer.

Eligible Conditions
  • Brain Cancer

ATTAC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer
Secondary outcome measures
Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes
Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions
Evidence of antigen-escape outgrowth in recurrent or progressive tumors
+3 more

ATTAC Trial Design

4Treatment groups
Experimental Treatment
Group I: Arm II (second randomization)Experimental Treatment2 Interventions
Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
Group II: Arm II (first randomization)Experimental Treatment1 Intervention
Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
Group III: Arm I (second randomization)Experimental Treatment1 Intervention
Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
Group IV: Arm I (first randomization)Experimental Treatment2 Interventions
Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tetanus toxoid
2006
Completed Phase 1
~50
therapeutic autologous lymphocytes
2006
Completed Phase 2
~300
therapeutic autologous dendritic cells
2006
Completed Phase 2
~550

Find a Location

Who is running the clinical trial?

Gary Archer Ph.D.Lead Sponsor
11 Previous Clinical Trials
250 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,111 Total Patients Enrolled
Katherine Peters, MD, PhDPrincipal InvestigatorDuke Univeristy Medical Center
6 Previous Clinical Trials
324 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Clinical Cancer ResearchJournal
Long-term Survival in Glioblastoma with Cytomegalovirus Pp65-targeted Vaccination
Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, Luis Sanchez-Perez, Smita K. Nair, Robert J. Schmittling, Pam Norberg, et al.. 2017. “Long-term Survival in Glioblastoma with Cytomegalovirus Pp65-targeted Vaccination”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-16-2057.
NatureJournal
Tetanus Toxoid and CCL3 Improve Dendritic Cell Vaccines in Mice and Glioblastoma Patients
Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al.. 2015. “Tetanus Toxoid and CCL3 Improve Dendritic Cell Vaccines in Mice and Glioblastoma Patients”. Nature. Springer Science and Business Media LLC. doi:10.1038/nature14320.
clinicaltrials.govStudy
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Gary Archer Ph.D. 2006. "Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00639639.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top